[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Third Affiliated Hospital of Southern Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":133},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,76,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100646039","remifentanil-and-dexmedetomidine-for-early-intensive-blood-pressure-lowering-in-ich-100646039",false,"NCT07695220","REmifentanil And Dexmedetomidine for EarlY Intensive Blood Pressure Lowering in ICH.","Efficacy and Safety of an Early Intensive Blood Pressure-Lowering Strategy Using Remifentanil and Dexmedetomidine in Patients With Spontaneous Intracerebral Hemorrhage: A Multicenter, Prospective, Superiority, Randomized Controlled Trial","READY-ICH","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Acute intracerebral hemorrhage confirmed by non-contrast head computed tomography.\n3. Symptom onset ≤ 6 h before randomization.\n4. At least two systolic blood pressure ≥ 150 mmHg separated by \\> 2 min prior to randomization.\n5. Admission to a monitored unit capable of active acute care (e.g., acute stroke unit, emergency department, or intensive care unit).\n6. Written informed consent provided by the patient or legally authorized representative.\n\nExclusion Criteria:\n\n1. Contraindication to intensive blood-pressure lowering (e.g., severe stenosis of carotid, vertebral, or cerebral arteries; Moyamoya disease; Takayasu arteritis; critical aortic stenosis).\n2. Clear evidence that the hemorrhage is secondary to a structural brain abnormality (arteriovenous malformation, aneurysm, tumor, trauma, infarct) or recent thrombolysis.\n3. Ischemic stroke within the preceding 30 days.\n4. Very high probability of death within 24 h based on clinical and\u002For radiologic criteria.\n5. Known advanced dementia or pre-stroke disability (pre- modified Rankin Scale score ≥ 3).\n6. Coagulopathy due to medication or hematologic disorder.\n7. Comorbid conditions that would interfere with outcome assessment or follow-up (e.g., active malignancy, end-stage organ failure).\n8. Known hypersensitivity to remifentanil or dexmedetomidine.\n9. Pregnancy or lactation.\n10. Concurrent participation in another investigational drug or device trial.\n11. Patient or legally authorized representative unwilling or unable to provide informed consent, or judged unlikely to comply with study procedures or follow-up.","ALL","18 Years",{"count":20,"type":21},1116,"ESTIMATED","INTERVENTIONAL",[24],"NA","Intracerebral hemorrhage (ICH) remains the most devastating subtype of stroke, with a case fatality rate of approximately 40% at one months post-onset, imposing a particularly heavy medical and economic burden on low- and middle-income countries. Studies have shown that poor prognosis in ICH patients is associated with acute blood pressure elevation and hematoma expansion after onset. Blood pressure control during the acute phase is considered a potentially key therapeutic strategy for improving outcomes in ICH patients; however, no clinical study has yet demonstrated a clear advantage of any specific antihypertensive agent or combination. Previous researchers have confirmed that the combined use of remifentanil and dexmedetomidine, while providing effective analgesia, sedation, and anti-sympathetic effects, could reduce dramatic fluctuations in blood pressure and heart rate, thereby facilitating more stable blood pressure reduction and potentially further improving functional outcomes in ICH patients. The investigators plan to conduct a multicenter, prospective, randomized controlled, superiority clinical trial within mainland China to evaluate the efficacy and safety of an early intensive blood pressure-lowering strategy using remifentanil combined with dexmedetomidine for improving functional prognosis in acute ICH patients. This study aims to provide evidence-based medical support for the use of remifentanil combined with dexmedetomidine in early intensive blood pressure-lowering in patients with ICH, to enrich the available options for early intensive blood pressure-lowering strategies, to improve the adverse prognosis of patients.",[27],"Intracerebral Hemorrhage",[29,30,31,32],"Intracerebral hemorrhage","Remifentanil","Dexmedetomidine","Blood pressure-lowering","NOT_YET_RECRUITING","2026-07-05",{"date":36,"type":37},"2026-07-10","ACTUAL",{"date":39,"type":21},"2026-07-31",{"date":41,"type":21},"2028-12-31",{"name":43,"class":44},"The Third Affiliated Hospital of Southern Medical University","OTHER_GOV",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100639241","comparative-analysis-of-two-transforaminal-lumbar-interbody-fusion-tlif-procedures-in-the-treatment-of-single-level-lumbar-spinal-stenosis-lss-a-single-center-prospective-randomized-controlled-trial-100639241","NCT07588555","Comparative Analysis of Two Transforaminal Lumbar Interbody Fusion (TLIF) Procedures in the Treatment of Single-Level Lumbar Spinal Stenosis (LSS): A Single-Center, Prospective, Randomized Controlled Trial","Comparative Analysis of L-Unitary Soft Endoscope Transforaminal Lumbar Interbody Fusion (LUSE-TLIF) Versus Minimally Invasive Transforaminal Lumbar Interbody Fusion (MIS-TLIF) in the Treatment of Single-Level Lumbar Spinal Stenosis (LSS): A Single-Center, Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ranging from 40 to 70 years, irrespective of sex.\n* Presence of bilateral lower-limb pain and neurogenic claudication, with or without low back pain.\n* Preoperative computed tomography or magnetic resonance imaging confirming single-level lumbar spinal stenosis accompanied by grade II or higher lumbar spondylolisthesis and\u002For lumbar instability.\n* Persistent pain within 7 days prior to enrollment, with inadequate response to nonsurgical treatment for more than 3 months.\n* Willingness to provide written informed consent and ability to comply with the study protocol and visit schedule.\n\nExclusion Criteria:\n\n* Patients with evidence of vascular claudication identified by lower-limb color Doppler ultrasound.\n* Patients with a history of previous lumbar spine surgery.\n* Coexistence of severe lumbar disc herniation, spinal deformity, spinal tumor, infection, or inflammatory diseases.\n* Pregnancy or lactation.\n* Presence of severe underlying medical conditions or psychiatric disorders that preclude tolerance of the procedure.\n* Known concurrent diseases considered by the investigator to preclude study entry.\n* Inability to comply with study assessments or complete questionnaires for any reason.\n* Patients deemed unsuitable for participation in this trial as judged by the investigator.","40 Years","70 Years",{"count":55,"type":21},276,[24],"Lumbar spinal stenosis (LSS), a common degenerative lumbar condition characterized by low back pain, leg pain, and neurogenic claudication, significantly impairs patients' quality of life. Its prevalence continues to rise with the aging population. For patients who do not respond to conservative treatment, surgical intervention remains a key therapeutic approach, with lumbar interbody fusion (LIF) being a commonly employed procedure. The technique has evolved from posterior lumbar interbody fusion (PLIF) to transforaminal lumbar interbody fusion (TLIF) and, more recently, to minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF). Although MIS-TLIF can effectively reduce tissue trauma and complications, it still faces clinical challenges such as intraoperative visual blind spots and the potential for postoperative chronic back pain associated with reliance on conventional pedicle screws. To address these limitations, our research team independently developed a highly integrated, miniaturized (with an outer diameter of only 1.8 mm), and maneuverable L-Unitary Soft Endoscope (LUSE) minimally invasive system. Its unique design helps avoid obstruction of the surgical field and allows flexible adjustment during the procedure. Currently, there is a lack of clinical efficacy evaluations in China on the use of this LUSE system for TLIF surgery (referred to as LUSE-TLIF) in treating LSS. Therefore, this study aims to systematically compare LUSE-TLIF with the currently mainstream MIS-TLIF, evaluating its safety, efficacy, and clinical outcomes in the treatment of LSS, in order to provide spine surgeons with a novel and potentially superior minimally invasive surgical option.",[59],"Lumbar Spinal Stenosis",[61,62,63,64,65],"Lumbar spinal stenosis","LUSE-TLIF","MISTLIF","Lumbar Spondylolisthesis","Lumbar Instability","RECRUITING","2026-05-08",{"date":69,"type":37},"2026-05-14",{"date":71,"type":37},"2026-03-18",{"date":73,"type":21},"2031-12-31",{"name":43,"class":44},1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":105,"locationsCount":75},"100574394","phase-1-safety-and-efficacy-of-fourth-generation-car-t-in-the-treatment-of-hematologic-malignancies-100574394","NCT06758713","Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies","Inclusion Criteria:\n\nSubjects must meet all of the following criteria to be enrolled:\n\n1\\. Voluntarily participate in this clinical study and sign the informed consent form; 2. 18 to 75 years old (including cut-off value), Male and female;; 3. Expected survival of at least 3 months; 4.1 CD19-positive B lymphocyte-derived hematologic malignancies; 4.2 Multiple myeloma patients; 4.3 Non-B cell-derived hematologic malignancies patients with CD7 or other target molecules; 5. The clinical trial values during the screening period meet the following criteria:\n\n1. White blood cell count ≥ 3.0 × 10e9\u002FL; Absolute neutrophil ≥ 1.0 × 10e9\u002FL; Lymphocyte count ≥ 0.5 × 10e9\u002FL. (The growth factor support is allowed, but growth factor must not have been received within 7 days prior to laboratory testing);\n2. Platelet count ≥ 50 × 10e9\u002FL (No blood transfusion support within 7 days prior to laboratory tests.); Note: Patients with leukemia, multiple myeloma, and lymphoma are not subject to the above blood picture requirements;\n3. Biochemical indicators Serum total bilirubin (TBIL) ≤ 2.5 ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ULN, or 5 ULN if liver dysfunction is primarily due to tumor invasion); 6. Cardiac function: Subjects must have good hemodynamic stability, left ventricular ejection fraction (LVEF) ≥ 55%; 7. Lung condition: Subjects are not serious infections such as severe pneumonia; 8. ECOG activity status score: 0-2 points; 9. Female subjects must use effective contraception (such as oral prescription contraceptives, injectable contraceptives, intrauterine devices, double blockade, contraceptive patches, male partner sterilization) throughout the study period; Must have a negative serum or urine pregnancy test result at screening and throughout the study.\n\nExclusion Criteria:\n\nAny one of the following conditions cannot be selected as a subject:\n\n1. Having received CAR-T therapy targeting the same molecule;\n2. Having received other immunotargeted therapy targeting the same molecules;\n3. Pregnant or lactating women;\n4. Subjects who have previously suffered from other malignancies, with the following exceptions:\n\n   1. Having received curative therapy, and no known active disease in the ≥ 3 years prior to the enrollment;\n   2. Non melanoma skin cancer subjects who have completed sufficient treatment and no evidence of thecurrent disease;\n5. Subjects with a severe mental disorder;\n6. Subjects with active autoimmune disease requiring immunotherapy;\n7. Having received allogeneic hematopoietic stem cell transplantation;\n8. Subjects with significant cardiovascular diseasesa.uncontrolled or symptomatic arrhythmias, congestive heart failure, or any heart disease with cardiac function grade 3 or grade 4 (according to the functional classification method of the New York Heart Association NYHA); b. Myocardial infarction or coronary artery bypass grafting within 6 months prior to screening); c. Clinically significant history of ventricular arrhythmia or unexplained syncope (non vaso-vagal or not due to dehydration);\n9. Subjects with active infectious disease including positive Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb) and peripheral blood Hepatitis B virus(HBV) DNA titer is ≥500IU\u002FmL, hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive, human immunodeficiency virus(HIV) antibody positive, syphilis primary screening antibody positive, active pulmonary tuberculosis; or with any significant infection requiring high-grade antibiotics Event;\n10. Subjects with dysfunction of important organssuch as organ function in the following abnormalities:\n\n    1. Serum AST or ALT \\> 2.5×ULN, or \\> 5ULN if liver function is predominantly due to tumor invasion; TBIL \\> 2.5 × ULN, unless the subject is Gilbert's syndrome;\n    2. Serum creatinine\\>2.5mg\u002Fdl;\n    3. Partial prothrombin time or activated partial thromboplastin time or international normalized ratio \\> 1.5×ULN in the absence of anticoagulant therapy;\n11. Participation in other clinical studies or prior treatment with any gene therapy product in the past three months;\n12. Subjects with uncontrolled diabetes mellitus (glycosylated hemoglobin HbAlc \\>8% at screening);13. Highly allergic constitution or history of severe allergies, and having contraindications to cyclophosphamide or fludarabine;\n\n14\\. Feasibility assessment screening demonstrated \\\u003C10% transfection of targeted lymphocytes or underamplification under CD3 \u002F CD28 costimulation (\\\u003C5-fold); 15. Subjects who are considered unsuitable to participate in this trial by the investigator.","75 Years",{"count":84,"type":21},60,[86],"PHASE1","This is a single center, open-label, dose-escalation\u002Fexpansion clinical study to evaluate the safety and effectiveness of Fourth-Generation CAR-T, and determine the recommended dose of the CAR T-cells for patients with Multiple Myeloma，B-cell lymphoma and other hematologic malignancies.",[89,90,91],"Multiple Myeloma","B-cell Lymphoma","Hematological Malignancy",[93,94,95,96,97,98],"Multiple myeloma","B-cell lymphoma","Hematological malignancy","CAR-T","Safety","Efficacy","2025-01-03",{"date":101,"type":37},"2025-01-06",{"date":103,"type":21},"2025-01-15",{"date":41,"type":21},{"name":43,"class":44},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":75},"100511668","autologous-costal-osteochondral-transplantation-for-talar-osteochondral-lesions-100511668","NCT05942430","Autologous Costal Osteochondral Transplantation for Talar Osteochondral Lesions","Evaluation of the Effectiveness and Safety of Autologous Costal Osteochondral Transplantation in the Treatment of Talar Osteochondral Lesions: a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Symptomatic Hepple stage V talar osteochondral lesions with a lesion depth ≥5 mm and an AOFAS score ≤80 points;\n* Failed conservative treatment for at least 6 months;\n* Unilateral talar osteochondral lesions without corresponding lesions on the tibial side;\n* Willingness to participate in this clinical trial and signing an informed consent form.\n\nExclusion Criteria:\n\n* Combined with lower limb deformity.\n* Combined with hip or knee joint diseases.\n* Combined with ipsilateral ankle arthritis with joint space narrowing .\n* Diagnosis of gouty arthritis of the ankle joint.\n* Combined with osteoporosis (T score \\\u003C-2.5).\n* Other conditions considered inappropriate for participation in this clinical trial by the researchers.","60 Years",{"count":115,"type":21},50,[24],"The goal of this clinical trial is to evaluate the effectiveness and safety of autologous costal osteochondral transplantation in the treatment of Hepple Stage V talar osteochondral lesions, compared with autologous osteoperiosteal transplantation. The main question it aims to answer is:\n\n• Whether autologous costal osteochondral transplantation can achieve better clinical outcomes and cartilage repair quality with lower donor site morbidity than autologous osteoperiosteal transplantation in the treatment of Hepple Stage V talar osteochondral lesions.\n\nParticipants will be randomly assigned to the intervention group (undergoing autologous costal osteochondral transplantation) or the control group (undergoing autologous osteoperiosteal transplantation). Both groups of participants will receive the same postoperative rehabilitation process and follow-up evaluation.",[119],"Articular Cartilage Defect",[121,122,123,124],"costa","autologous osteochondral transplantation","autologous osteoperiosteal transplantation","osteochondral lesion of the talus","2023-09-04",{"date":127,"type":37},"2023-09-06",{"date":129,"type":37},"2023-09-01",{"date":131,"type":21},"2028-02",{"name":43,"class":44},""]